KEYSTONE BIO

Altering the Course of Disease

Using KB proprietary methods, KB has identified and eliminates a primary driver of our most deadly diseases, Porphyromonas gingivalis and all of it's unique virulence factors.



KB is changing the paradigm of inflammatory based disease with precision bio-therapeutics and diagnostics to eliminate a chronic, foreign, bacterial source in the body thereby reducing systemic inflammation.

Using KB proprietary methods, KB has identified a bacterial toxic protein that is a primary driver of systemic inflammation. This bacterial toxic protein complex is secreted actively in large amounts by the bacteria for it's own survival, however has off site systemic pathology in various end organs such as the brain in AD brain tissues. This virulent protein complex is packaged into distinct outer membrane vesicles, breaking down and crossing the BBB, and impacts the brain parenchyma in specific neuro-anatomic locations consistent with AD development. Those same toxic proteins are delivered throughout the body from their source, spreading systemic inflammation up to and including end organ disease.

KB has the only Precision Biologic on the planet that's been shown to eliminate them at their source.



Chronic inflammatory diseases have been recognized as the most significant cause of death in the world today, with **more than 50% of all deaths being attributable to inflammation-related diseases** such as ischemic heart disease, stroke, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease (NAFLD) and autoimmune and neurodegenerative conditions.

KEYSTONE BIO

Developments



KB-001

Monoclonal antibody with unique binding to P. gingivalis toxin/survival complex KB-001 has already been shown in its first clinical study to prevent long term recolonization, thereby eliminating all of the virulence factors of P.g. contributing to systemic/organ-based inflammation at their source.

KBhu-007 and KBhu-0014

Humanized chimeric monoclonal antibody candidates with similar binding to Porphyromonas gingivalis, ready for drug development.

KBd-001 and KBd-002

Two Companion of diagnostics -one for genotyping the bacteria and one for measuring the toxic vesicles in the blood. — in development.

KBvx-001

Vaccine development targeting same protein complex as KB-001 Mab.